Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: )

• Drug Name: Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Metastatic colorectal cancer	2B91	Phase 3	[1]
Non-small-cell lung cancer	2C25.Y	Phase 3	[1]
Hepatocellular carcinoma	2C12.02	Phase 2	[2]
Hypopharyngeal squamous cell carcinoma	2B6D.0	Phase 1/2	[3]

• Cross-matching ID: TTD Drug ID

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor A (VEGFA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Central retinal vein occlusion with macular edema		Approved	[5]
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[6]
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[7]
Ranibizumab	DMSYPNW	Central retinal vein occlusion with macular edema		Approved	[8]
Bevacizumab	DMSD1UN	Adenocarcinoma	2D40	Approved	[9]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[10]
PTC299	DMP9TKE	Rheumatoid arthritis	FA20	Phase 2	[11]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[12]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[13]
Abicipar pegol	DM59OJ2	Diabetic macular edema	9B71.02	Phase 2	[14]

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[15]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[16]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[17]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[18]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[20]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[21]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[22]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[20]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[23]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[4]
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Inhibitor	[4]

References

• [1] ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
• [2] ClinicalTrials.gov (NCT01130519) A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT00055913) Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
• [4] Clinical pipeline report, company report or official report of Roche (2009).
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [7] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [8] Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
• [9] FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
• [10] Clinical pipeline report, company report or official report of Genentech (2009).
• [11] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
• [12] Bispecific antibodies and their applications
• [13] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [16] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [17] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [18] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [19] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [21] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [22] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [23] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).